DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR RETACRIT
» See Plans and Pricing
All Clinical Trials for RETACRIT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03598582 | Biological Predictive Factors of Response to ESA in Low Risk MDS Patients | Completed | Association pour la recherche sur les Affections Malignes en Immunologie Sanguine | Phase 4 | 2013-01-01 | In this trial, the investigators would like to understand why a small percentage of patients will be refractory to ESA (independently of International prognostic scoring system (IPSS) and % of blasts). In a retrospective study of the "Groupe Francophone des Myélodysplasies (GFM)" , the investigators showed that about 43% of patients are refractory or will relapse after initial response to ESA and it has been shown that these patients have a poorer survival. The investigators plan to give a 12-week treatment of Epoetin alfa or zeta in low risk MDS patients and measure different biological factors to predict response to ESA: - evaluation by flow cytometry before and after treatment of the degree of dyserythropoiesis and dysgranulopoiesis which could explain the primary resistance or loss of response of a subset of patients, - screening by molecular biology of predictive factors of response to ESA, - Iron homeostasis will be measured via hepcidin, GDF-15 and ferritin levels. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for RETACRIT
Condition Name
Clinical Trial Progress for RETACRIT
Clinical Trial Phase
Clinical Trial Sponsors for RETACRIT
Sponsor Name
